

# Yasuhiro Kaneda

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7426494/yasuhiro-kaneda-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

48  
papers

1,600  
citations

18  
h-index

39  
g-index

48  
ext. papers

1,746  
ext. citations

4.7  
avg, IF

4.08  
L-index

#	Paper	IF	Citations
48	Serotonin receptors: their key role in drugs to treat schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2003</b> , 27, 1159-72	5.5	592
47	Brief assessment of cognition in schizophrenia: validation of the Japanese version. <i>Psychiatry and Clinical Neurosciences</i> , <b>2007</b> , 61, 602-9	6.2	166
46	Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism in schizophrenia is associated with age at onset and symptoms. <i>Neuroscience Letters</i> , <b>2006</b> , 401, 1-5	3.3	84
45	Predictors of subjective and objective quality of life in outpatients with schizophrenia. <i>Psychiatry and Clinical Neurosciences</i> , <b>2008</b> , 62, 404-11	6.2	67
44	Subjective and objective quality of life, levels of life skills, and their clinical determinants in outpatients with schizophrenia. <i>Psychiatry Research</i> , <b>2008</b> , 158, 19-25	9.9	62
43	Schizophrenia Quality of Life Scale: validation of the Japanese version. <i>Psychiatry Research</i> , <b>2002</b> , 113, 107-13	9.9	55
42	Quality of life and cognitive dysfunction in people with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2011</b> , 35, 53-9	5.5	41
41	The hypothalamic-pituitary-adrenal axis in chronic schizophrenic patients long-term treated with neuroleptics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2002</b> , 26, 935-8	5.5	41
40	Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2011</b> , 35, 78-83	5.5	40
39	Determinants of work outcome in schizophrenia and schizoaffective disorder: role of cognitive function. <i>Psychiatry Research</i> , <b>2009</b> , 169, 178-9	9.9	37
38	Effects of chronic neuroleptic administration on the hypothalamo-pituitary-gonadal axis of male schizophrenics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2000</b> , 24, 251-8	5.5	34
37	Subjective and objective measures of quality of life have different predictors for people with schizophrenia. <i>Psychological Reports</i> , <b>2006</b> , 99, 477-87	1.6	30
36	Criterion and construct validity of the CogState Schizophrenia Battery in Japanese patients with schizophrenia. <i>PLoS ONE</i> , <b>2011</b> , 6, e20469	3.7	29
35	Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery: validation of the Japanese version. <i>Psychiatry and Clinical Neurosciences</i> , <b>2013</b> , 67, 182-8	6.2	26
34	Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2012</b> , 36, 300-6	5.5	24
33	Psychometric properties of the Japanese version of the Calgary Depression Scale for Schizophrenics. <i>Journal of Nervous and Mental Disease</i> , <b>2000</b> , 188, 237-9	1.8	21
32	Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment. <i>Psychiatry Research</i> , <b>2010</b> , 178, 57-62	9.9	20

31	Levodopa improved rapid eye movement sleep behavior disorder with diffuse Lewy body disease. <i>General Hospital Psychiatry</i> , <b>2003</b> , 25, 140-2	5.6	18
30	Clinical correlates associated with cognitive dysfunction in people with schizophrenia. <i>Psychiatry and Clinical Neurosciences</i> , <b>2012</b> , 66, 491-8	6.2	17
29	Verbal working memory impairment in patients with current episode of unipolar major depressive disorder and in remission. <i>Clinical Neuropharmacology</i> , <b>2009</b> , 32, 346-7	1.4	17
28	Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia. <i>Human Psychopharmacology</i> , <b>2012</b> , 27, 90-100	2.3	15
27	Neurocognitive Impairments Are More Severe in the Binge-Eating/Purging Anorexia Nervosa Subtype Than in the Restricting Subtype. <i>Frontiers in Psychiatry</i> , <b>2018</b> , 9, 138	5	14
26	No relationship between testosterone levels and depressive symptoms in aging men. <i>European Psychiatry</i> , <b>2002</b> , 17, 411-3	6	13
25	Serotonin syndrome - potential role of the CYP2D6 genetic polymorphism in Asians. <i>International Journal of Neuropsychopharmacology</i> , <b>2002</b> , 5, 105-6	5.8	12
24	Effects of risperidone on gonadal axis hormones in schizophrenia. <i>Annals of Pharmacotherapy</i> , <b>2001</b> , 35, 1523-7	2.9	11
23	Platelet serotonin concentrations in medicated schizophrenic patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2001</b> , 25, 983-92	5.5	11
22	Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms. <i>Human Psychopharmacology</i> , <b>2006</b> , 21, 439-45	2.3	10
21	Possible relationship between testosterone and comorbid major depressive episode in male patients with schizophrenia treated with typical antipsychotic medications. <i>Clinical Neuropharmacology</i> , <b>2003</b> , 26, 291-3	1.4	10
20	The serotonin syndrome: investigation using the Japanese version of the Serotonin Syndrome Scale. <i>Psychiatry Research</i> , <b>2001</b> , 105, 135-42	9.9	10
19	Mild serotonin syndrome on fluvoxamine. <i>International Journal of Neuroscience</i> , <b>2001</b> , 109, 165-72	2	10
18	Relationship between social and cognitive functions in people with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , <b>2018</b> , 14, 2215-2224	3.1	8
17	Long-term efficacy and safety of blonanserin in patients with first-episode schizophrenia: a 1-year open-label trial. <i>Psychiatry and Clinical Neurosciences</i> , <b>2014</b> , 68, 841-849	6.2	7
16	Impact of risperidone medication on quality of life and gonadal axis hormones in schizophrenia male patients with acute exacerbation. <i>International Journal of Neuropsychopharmacology</i> , <b>2003</b> , 6, 247-52	5.8	7
15	Possible mild serotonin syndrome related to co-prescription of tandospirone and trazodone. <i>General Hospital Psychiatry</i> , <b>2001</b> , 23, 98-101	5.6	7
14	Suicidality in schizophrenia as a separate symptom domain that may be independent of depression or psychosis. <i>Schizophrenia Research</i> , <b>2006</b> , 81, 113-4	3.6	5

13	The impact of prolactin elevation with antipsychotic medications on subjective quality of life in patients with schizophrenia. <i>Clinical Neuropharmacology</i> , <b>2003</b> , 26, 182-4	1.4	5
12	Differences in waveforms of cerebral evoked potentials among healthy subjects, schizophrenics, manic-depressives and epileptics. <i>Journal of Medical Investigation</i> , <b>2007</b> , 54, 303-15	1.2	5
11	Verbal working memory and functional outcome in patients with unipolar major depressive disorder. <i>World Journal of Biological Psychiatry</i> , <b>2009</b> , 10, 591-4	3.8	4
10	Depressive symptoms in chronic schizophrenia patients: any differences between patients with and without a major depressive episode?. <i>European Psychiatry</i> , <b>2003</b> , 18, 137-9	6	4
9	Correlation between plasma homovanillic acid levels and the response to atypical antipsychotics in male patients with schizophrenia. <i>Clinical Neuropharmacology</i> , <b>2005</b> , 28, 262-4	1.4	3
8	Neurocognitive profile of euthymic Japanese patients with bipolar disorder. <i>Psychiatry and Clinical Neurosciences</i> , <b>2017</b> , 71, 373-382	6.2	2
7	Effects of quetiapine on gonadal axis hormones in male patients with schizophrenia: a preliminary, open study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2003</b> , 27, 875-8	5.5	2
6	Quetiapine impact on quality of life in patients with schizophrenia. <i>Annals of Pharmacotherapy</i> , <b>2003</b> , 37, 917-8	2.9	2
5	No significant association between brain-derived neurotrophic factor gene rs6265 and cognitive function in Japanese patients with schizophrenia. <i>Psychiatry Research</i> , <b>2014</b> , 215, 803-5	9.9	1
4	Repetitive behaviors in chronic schizophrenia: using the Japanese version of the Elgin Behavior Rating Scale (JEBRS). <i>International Journal of Neuroscience</i> , <b>2003</b> , 113, 879-90	2	1
3	A short version of the measurement and treatment research to improve cognition in schizophrenia consensus cognitive battery. <i>Schizophrenia Research</i> , <b>2013</b> , 150, 600-1	3.6	0
2	Retraction: Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia. <i>Human Psychopharmacology</i> , <b>2017</b> , 32, e2622	2.3	0
1	Predictors of life skills in people with schizophrenia. <i>Journal of Medical Investigation</i> , <b>2020</b> , 67, 75-82	1.2	